Indiana University School of Medicine Indianapolis, IN
Meera Iyengar, MD1, Wade Billings, MD1, Matthew Bohm, DO2 1Indiana University School of Medicine, Indianapolis, IN; 2Indiana University Hospital, Indianapolis, IN
Introduction: Inflammatory bowel disease (IBD) is a group of chronic inflammatory conditions that affects over one million Americans. While biologic therapies have improved outcomes for patients with IBD as a whole, there is conflicting data on if obesity is an independent factor on the effectiveness of biologic therapy in IBD1,2. Our aim was to see if BMI, as a surrogate for obesity, was associated with higher healthcare utilization following the initiation of biologic therapy.
Methods: Retrospective cohort study between 12/15/10-7/1/17 of subjects diagnosed with IBD patients based on ICD9-10 codes, on biologics, with at least >1 year of follow-up using the validated Indiana Network for Patient Care research database. Logistic regression was used to calculate odds ratios for ED visits, hospitalizations, surgery, steroids, and opioids for the year following initiation of biologic therapy.
Results: 1,838 patients were included. Mean age was 47.0 (+18.8). Obese individuals were more likely to be female (59.1% vs. 52.9%; p< 0.001), Black (8.9% vs. 6.3%; p< 0.001), and non-smokers (49.2% vs. 40.3%; p< 0.001). Logistic regression models found those with a BMI >30, compared to those with BMI < 30, had higher odds of ED visits (OR 1.48 95% CI [1.09-2.00]; p=0.01) and opioid orders (OR 1.54 95% CI [1.23-1.92]; p=0.0001). Rates of hospital visits, IBD surgeries, and steroid orders did not significantly differ.
Discussion: A BMI >30 was associated with marginally higher odds of ED visits and opioid orders with no differences found for other outcomes. Our findings add to evidence from prior studies showing that obesity is possibly linked to inferior outcomes in patients with IBD on biologics.
Disclosures:
Meera Iyengar indicated no relevant financial relationships.
Wade Billings indicated no relevant financial relationships.
Matthew Bohm indicated no relevant financial relationships.
Meera Iyengar, MD1, Wade Billings, MD1, Matthew Bohm, DO2. P3614 - The Impact of Obesity on Healthcare Utilization in Patients with Inflammatory Bowel Disease on Biologics, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.
